Skip to main content

Home/ Groups/ Pharmaceutical Laboratory
Rss Feed
Sort By: Most Recent | Popular Filter: All | Bookmarks | Topics Simple Middle
3More

Paying the price | DAWN.COM - 0 views

dawn.com/...paying-the-price
shared by hamelinclara on 20 Jan 13 - No Cached
  • Price freeze or not, it is true that prices of medicine have increased over the years and often the consumer ends up paying double the original price to a retailer, due to shortage. Manufacturers and market players put the blame on each other for shortage knowing that there won’t be any action from the government
  • While keeping a price freeze for many years, the government has been allowing price surges to the manufacturers under hardship cases.
  • He states that it is natural that pharma companies slow down the manufacture of a product on which they are incurring losses or barely breaking even
1More

Pharma Marketing Blog: Drop TV Ads, Says John LaMattina, Former Pfizer President of R&D - 0 views

pharmamkting.blogspot.fr/...ays-john-lamattina-former.html pharma marketing ads tv
shared by hamelinclara on 20 Jan 13 - No Cached
  • The other 3 fixes LaMattina put on a par with dropping TV ads are Transparency of payments to healthcare professionals,  Transparency of clinical trial data, and  Stop the illegal detailing of drugs 
2More

Pressure mounts to end US pharma pay-for-delay deals - FRANCE 24 - 0 views

www.france24.com/...-end-us-pharma-pay-delay-deals
shared by hamelinclara on 20 Jan 13 - No Cached
  • US senators are introducing legislation to end pay-off deals that keep generic drugs off shelves and give pharmaceutical giants market exclusivity that costs consumers billions of dollars per year.
  • pay-for-delay" agreements
7More

Pharmaceuticals: Companies will focus on external partnerships to improve productivity ... - 0 views

cen.acs.org/...cus-external-partnerships.html phara 2012 2013
shared by hamelinclara on 20 Jan 13 - No Cached
  • If the buzzword for the pharmaceutical industry in 2012 was “patent cliff,” the key theme for 2013 is “partnership.”
  • maller R&D organizations and budgets, drug companies are putting more emphasis on working relationships with biotech firms or with academia
  • collaboration
  • ...4 more annotations...
  • pharmaceutical leader for the consulting firm Ernst & Young.
  • Patrick Flochel
  • While trying to make their own research efforts more productive, companies are filling gaps in their drug pipelines through acquisitions.
  • n exception may be AstraZeneca, which lost its patent for the antipsychotic drug Seroquel and was hit hard by generics competition. “AstraZeneca is in a pretty dire situation,” Latwis says.
1More

PharmTech Talk » Social Media and the Pharma Industry - 0 views

blog.pharmtech.com/...-media-and-the-pharma-industry pharma social media
shared by hamelinclara on 17 Jan 13 - No Cached
  • For the pharmaceutical industry, social media poses concerns that range from release of propriety information to regulatory constraints to patient safety. These concerns have limited the industry’s use of a potential marketing and networking tool. Other industries are using Twitter, Facebook, and other social media outlets to promote products, follow consumer trends, and connect directly with their consumers. Is social media being used effectively at all in the pharmaceutical industry? Are there ways social media can be positively used by industry members to share ideas, connect with industry members, or even promote products? And if there is a fear of regulatory infractions, what can or should FDA and other international regulatory agencies do to promote the use of social media?
3More

PharmTech Talk » Pharma's Reputation in Decline - 0 views

blog.pharmtech.com/...2%80%99s-reputation-in-decline reputation pharma
shared by hamelinclara on 17 Jan 13 - No Cached
  • Respondents indicated several reasons for the overall decline: inappropriate marketing of drugs perceived lack of transparency, especially in reporting results from clinical trials some drug prices are still unaffordable to many patients and payers, giving the general impression that profit comes before patients.
  • Drug development is expensive; far more expensive than many average patients and consumers will ever understand
  •   patient-centredness, patient information, patient safety, useful products, transparency and integrity, so these represent good areas for companies seeking to boost their reputation to scrutinise.
1More

Pharmaceutical industry would grow at 19% in 2013: Morgan Stanley - Economic Times - 0 views

articles.economictimes.indiatimes.com/...rma-equalweight-morgan-stanley pharma morgan
shared by hamelinclara on 17 Jan 13 - No Cached
  • e expect the intellectual property investments in the past few years to start bearing fruits in US and EU markets in FY13. There will be new drug launches, new drug filings and Phase II clinic trials throughout the year.", said Samir Baisiwala, senior analyst with Morgan Stanley in his report. Also other markets such as Japan and other emerging markets could be other growth areas
6More

Trius: In An About Face, Congress Is Helping Biotech Companies That Are Developing Anti... - 0 views

seekingalpha.com/...hat-are-developing-antibiotics trius pharma US
shared by hamelinclara on 15 Jan 13 - No Cached
  • The implications for Trius (TSRX) and other leading biotechnology companies involved in antibiotics development are profound.
  • ost large pharmaceutical and biotechnology firms have avoided antibiotics for much of the past two decades in large part due to the intrusion of Congress into the regulatory process
  • The most visible sign of this shift in attitude came from Congress with the passage of the Generating Antibiotics Incentives Now Act or GAIN which became effective on October 1, 2012. This was intended to spur development of new antibiotics through streamlining a regulatory process which has been oppressive for much of the last decade. Responding to the prompting of Congress, I expect the FDA to approach regulatory approval of new antibiotics with the same sense of urgency as drugs for cancer. The end result will be quicker approval of new drugs and new indications for existing antibiotics.
  • ...3 more annotations...
  • Antibiotics were major drivers of sales growth for the pharmaceutical industry in the 1970s, 1980s and early 1990s which caught the attention of the industry's many critics. A consensus developed among politicians, consumer groups and payors that there was no need for new antibiotics as most bacteria were susceptible to existing products. They saw new antibiotics as offering no advantages over existing drugs even though they were priced many times higher. Faced with this hostile environment, drug companies began to de-emphasize antibiotic research and focus on trendy new areas like depression, cholesterol lowering, gastrointestinal reflux disease, etc.
  • Adding to the move away from antibiotic development was considerable scrutiny about side effects that the industry came under in the early part of the 2000s. A major catalyst for this was the Vioxx side effect issues that caused Merck (MRK) to withdraw this anti-inflammatory drug from the market in 2004
  • ooking beyond the GAIN Act, infectious disease experts, FDA and industry are working on proposals for a new restricted approval pathway that would speed the development of new antibacterial drugs and could address some of the economic disincentives that have driven most pharma companies out of the space. A drug's safety and effectiveness would be studied in substantially smaller, more rapid, and less expensive clinical trials, like those typically used to support Orphan Drug approvals. They would be narrowly indicated for use in small, well-defined populations of patients for whom the drugs' benefits have been shown to outweigh their risks. It would slash the number of patients required to gain approval from about 1,400 for the typical antibiotic indication to 100 or less, cut development time in half, and reduce regulatory uncertainty
5More

Generic companies facing some of the same issues as big pharma (part 1) - Medical Progr... - 0 views

www.medicalprogresstoday.com/...ssues-as-big-pharma-part-1.php pharma generic Bio
shared by hamelinclara on 15 Jan 13 - No Cached
  • But now the drugs in the headlines are generics. As the industry has grown and matured, it's faced greater scrutiny from regulatory agencies. Now it faces many of the same setbacks that plague their branded brethren.
  • Lipitor, Plavix, Lexapro and Seroquel
  • these same manufacturers are facing a patent cliff of their own
  • ...2 more annotations...
  • generics have been plagued by high-profile manufacturing and quality issues that have raised questions about the sector's safety and ultimate viability.
  • The market is increasingly complex for generic manufacturers, and business-as-usual isn't going to cut it. In my next post, I'll describe another critical issue facing these drugmakers and their relationship with regulatory agencies: moving into the new space of biologics.
1More

Pharma Has What Kind Of Corporate Reputation? // Pharmalot - 0 views

www.pharmalot.com/...kind-of-corporate-reputation-2 pharma reputation
shared by hamelinclara on 15 Jan 13 - No Cached
  • In fact, many patient groups referred to negative press to explain why they downgraded their opinion of some drugmakers, particularly concerning patient safety, transparency and corporate integrity. Drugmakers with a high exposure to ‘bad stories’ in 2012 saw their rankings drop, PatientView writes in its report. Others benefited as a result.
3More

"On prête bien du pouvoir aux laboratoires pharmaceutiques" - Metro - 0 views

www.metrofrance.com/...mman!6AKW5T9d0XMn2 LEEM Pharma
shared by hamelinclara on 14 Jan 13 - No Cached
  • D'abord, la France n'est plus la championne du monde des médicament
  • En volume, la consommation baisse même de 1% par an.
  • médical. Quant aux visiteurs médicaux, ce sont des professionnels formés et encadrés par une réglementation très stricte qui date de 2004.
2More

Pharmaceuticals, Patents, and the Media « Digifesto - 1 views

digifesto.com/...euticals-patents-and-the-media Pharma patents
shared by hamelinclara on 14 Jan 13 - No Cached
  • When Big Pharma puts out a $14 million dollar Super Bowl commercial, is that dipping into the research budget? Or is that part of a larger operating cost endured by these companies–the costs of making their brand a household name, of paying doctors to make subscriptions, and of lobbying for a congenial political climate?
  • how does one design a news dissemination network with mass appeal that both provides attractive content while minimizing potential for abuse by economic interests that are adversarial to the network users?
1More

Pharma industry 'strategic crisis' | Chemistry World - 1 views

www.rsc.org/...pharma-industry-strategy Emergents Pharma
shared by hamelinclara on 11 Jan 13 - No Cached
  • Emerging markets offer the biggest growth – their market share is set to rise to 40% by 2016. The market for pharmaceutical products will grow on average by 4.5% annually until 2016. But growth in emerging markets will increase by almost 12%. China, Brazil, India and Russia (the so-called BRIC economies) in particular are experiencing high growth.
1More

Drug companies forge partnerships with top schools | Wichita Eagle - 1 views

www.kansas.com/...panies-forge-partnerships.html Pharma schools
shared by hamelinclara on 11 Jan 13 - No Cached
  • Pfizer Inc., Astra Zeneca PLC and Eli Lilly and Co. are among the major international drug companies signing agreements with schools such as New York University, Harvard and the University of California at San Francisco
1More

Bayer HealthCare completes acquisition of Teva Pharmaceutical Industries' U.S... - 1 views

www.prnewswire.com/...health-business-185532622.html animal bayer pharma
shared by hamelinclara on 10 Jan 13 - No Cached
  • Bayer HealthCare completes acquisition of Teva Pharmaceutical Industries' U.S. animal health business
6More

Article > Global pharma "in strategic crisis," say companies - 1 views

www.pharmatimes.com/...egic_crisis_say_companies.aspx pharma stratégies
shared by hamelinclara on 10 Jan 13 - No Cached
  • Three out of four pharmaceutical companies believe their industry is in the midst of a strategic crisis, new research finds. Pricing and cost pressures, regulatory changes and patent expiries are leading to shrinking margins, and the biggest growth opportunities are to be found in the emerging markets, albeit with smaller margins, says the report, from Roland Berger Strategy Consultants.
  • "Pharmaceutical markets such as Europe and the US are stagnating due to rising price pressure, regulatory changes in the healthcare system and more stringent admission requirements, but in emerging markets we are seeing strong growth. Nevertheless, the margins here are lower and driven heavily by non-patent-protected products," says Roland Berger consultant Martin Erharter.
  • R&D costs have risen over 80% worldwide in the past 10 years
  • ...3 more annotations...
  • number of new product launches has dropped 43%; a
  • eturn on investment (ROI) in R&D is more or less negative
  • new products in emerging markets
« First ‹ Previous 321 - 340 of 411 Next › Last »
Showing 20▼ items per page